01:03

Thermogravimetric Analysis in Pharmaceuticals | Veeprho

00:56

Forced Degradation Studies for Drug Substances & Drug Products- Scientific Considerations | Veeprho

00:49

Potential Impurities in Drug Substance & Drug Products | Veeprho

01:03

Forced Degradation Studies for Drug Substances and Drug Products – A Regulatory Considerations

00:40

Nitrosamine Impurities and the Sartans | Veeprho

00:45

A Glimpse on Quality by Design (QbD) Approach in Pharmaceutical Industry | Veeprho

00:56

Recent Control and Testing Strategies for Genotoxic Impurities

00:35

Control of Pharmaceutical Impurities in Pharmaceutical Drug Products

01:10

Impurity Profiling in Drug Development

00:42

Impurities in Pharmaceutical Drug Substances

01:17

Clindamycin: Drug Information

00:42

Understanding the Classification of Potentially Mutagenic Impurities as per ICH M7 Guidelines

01:03

N-Nitroso Ticagrelor (CAS 2476859-55-7) Formation & Cyclized Impurity Insights

01:10

Pharmaceutical Staff Qualifications and Training: The Path to Effective Practice & Compliance

01:10

Laboratory Quality Testing: Best Practices & Compliance

01:59

Duloxetine Drug Information

01:31

Analytical Method Transfer

01:17

Determination of Response factors of Impurities in Drugs by HPLC

01:10

Nitrosamine Current Challenges and Way Forward

02:48

Chemically Bonded Phases in Chromatographic Silicas

03:02

Counter Current Chromatography

01:10

Good Documentation Practices in the Pharmaceutical Industry (GDocP)

02:06

Liquid-liquid extraction (LLE), supported liquid extraction (SLE), and solid-phase extraction (SPE)

00:42

Regulatory Updates from FDA and EDQM

01:03

Chromatographic Methods and Techniques

00:35

Chromatography Overview

01:38

Four Technological Advances Transforming Chemical Synthesis

02:27

Advancement in Chromatographic Columns Technique

01:24

EMA update on Nitrosamine Guidelines

01:52

High Performance Liquid Chromatography HPLC for Impurity Analysis

01:24

HPLC Columns and Their Role in Compound Separation

01:24

Qualification of Non Mutagenic Impurities

01:10

Metronidazole Drug Information

01:03

Posouzení rizika pro nečistoty Nitrosaminu

02:34

Everolimus Drug Information

00:49

Navigating the Nimesulide Landscape Impurities, Efficacy, and Regulatory Status

00:50

Demystifying Thiocolchicoside: Impurities, Uses, and Essential Insights

00:50

Comprehensive Guide to Paroxetine: Effectiveness, Side Effects, and Comparisons | Veeprho

00:56

Moxifloxacin Impurities and Key Attributes A Detailed Exploration

00:43

Delving into Darifenacin: Analyzing Impurities and Understanding Pharmacological Properties

00:43

Exploring Ketoprofen Impurities: Key Factors for Pharmaceutical Quality and Safety

00:43

Deciphering Linagliptin Impurities: Ensuring Drug Purity and Effectiveness in Diabetes Management

00:33

Exploring the Impact of Remdesivir Impurities: A Comprehensive Analysis of Safety and Side Effects

00:35

Sulfadiazine Explored: Impurities, Characteristics, and Clinical Applications

01:31

Computational approach for suitable surrogate selection to determine alternative Acceptable Intake

00:48

FDA Guidance for Industry on the AI Limits for Nitrosamine Drug Substance-Related Impurities

00:50

Unveiling the Purity and Potency of Chlorpheniramine: A Closer Look at Its Impurities & Applications

00:57

FDA guidance on M7(R2) Assessment and control of DNA-Reactive (Mutagenic) Impurities

01:25

Chlorpromazine Drug Information

01:25

Quantitative and Qualitative Analysis in Pharmaceuticals

01:39

Four Technological Advances Transforming Chemical Synthesis

00:50

Safe and Efficient Chemical Warehousing | Veeprho

01:38

Vancomycin Drug Information

01:32

Rifamycin Drug Information

00:57

The Role of Impurity Profiling in Therapeutic Peptides

01:38

Custom Synthesis in Pharmaceuticals: Advantages and Challenges

01:08

Navigating Quality Control in Clinical Trials for Reliable Results

01:18

Nitrosamine Impurities Challenges and Solution

00:54

Pharmacopeial Standards Ensuring Quality and Safety in Healthcare

00:37

Évaluation des risques liés aux impuretés nitrosamines